EULAR and the ERA–EDTA have published updated recommendations for the management of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Their recommendations include use of immunosuppressive therapy combined with glucocorticoids for remission induction; cyclosphosphamide and rituximab are considered to have similar efficacy. Plasma exchange is recommended for patients with rapidly progressive renal failure or severe diffuse pulmonary haemorrhage.
References
Yates, M. et al. EULAR/ERA–EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. http://dx.doi.org/10.1136/annrheumdis-2016-209133 (2016)
Rights and permissions
About this article
Cite this article
Aguilar, A. Management of AAV: updated recommendations. Nat Rev Nephrol 12, 444 (2016). https://doi.org/10.1038/nrneph.2016.102
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.102